|Bid||38.48 x 3000|
|Ask||38.51 x 2900|
|Day's Range||38.86 - 39.17|
|52 Week Range||37.43 - 50.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.86 (4.64%)|
|1y Target Est||N/A|
Moody's Investors Service, ("Moody's") has today assigned a first-time B3 corporate family rating (CFR) and a B3-PD Probability of Default Rating (PDR) to Al Sirona (Luxembourg) Acquisition S.a.r.l. ...
Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains
President Trump took heat for being too soft on drug companies in a speech last week. The Centers for Medicare and Medicaid Services on Tuesday, May 15, rolled out revamped Drug Spending Dashboards that likely will put pressure on drug companies to lower prices. The newly designed dashboards show how much is spent in Medicare Part B, Medicare Part D and Medicaid for name-brand drugs.
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
AstraZeneca’s (AZN) Cardiovascular and Metabolic Disease (or CVMD) segment includes various products such as Brilinta, Farxiga, Bydureon, Byetta, Onglyza, and Symlin and legacy products such as Atacand, Crestor, and Seloken.
A year ago LVMH, the owner of luxury brand Louis Vuitton, became France’s biggest company by market value, a mantle energy giant Total SA and drugmaker Sanofi SA had shared for almost a decade. Kering SA was nowhere in sight. A more than 200 percent rally since the start of 2016, and more than 70 percent over the past 12 months, has now put the owner of “it bag” brands within shouting distance of the top five stocks in the CAC 40 Index.
Genzyme recently cut 95 jobs in Framingham, while TJX and Staples, both headquartered in the city, have slashed a combined 477 workers in undisclosed locations.
The marijuana market in North America is growing at an astounding rate, with investors who are in the know set to reap most of the rewards
Investors pursuing a solid, dependable stock investment can often be led to Sanofi (NYSE:SNY), a large-cap worth US$94.36B. Doing business globally, large caps tend to have diversified revenue streams andRead More...
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
Warren Buffett is widely recognized as the greatest investor in the world, based on a decades-long record of outperformance, but he's the first to acknowledge that he's merely mortal, with more than his share of mistakes. The Oracle of Omaha announced in 2018 that Berkshire Hathaway completely exited its IBM position.
In 1Q18, Amgen’s (AMGN) Repatha revenue grew 15% YoY (year-over-year) to $123 million from $49 million, primarily due to higher unit demand. It grew ~26% quarter-over-quarter. In US and international markets, Repatha generated revenue of $84 million and $39 million, respectively, compared with $33 million and $16 million in 1Q17.
On April 30, the FDA granted priority review status to the sBLA (supplemental biologics license application) seeking approval for the combination of Merck’s (MRK) Keytruda, Eli Lilly’s (LLY) Alimta, and platinum-based chemotherapy agents like carboplatin or cisplatin in first-line metastatic NSCLC (non-squamous non-small cell lung cancer) indication. The Prescription Drug User Fee Act’s date is September 23. The sBLA is based on data from the Phase 3 KEYNOTE-189 trial declared on April 16. ...
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand. It grew ~8% QoQ (quarter-over-quarter).
Measuring Sanofi’s (ENXTPA:SAN) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations, whichRead More...
Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.
Regeneron reported better-than-expected adjusted earnings of $4.76 a share. The biotech's revenue of $1.51 billion came in a little below some forecasts.
Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.
Pfizer’s drug Viagra coming off patent protection is still the biggest headwind for PFE stock at the moment. PFE lost its exclusivity for Viagra in December and is the primary reason for the company reporting revenues dropping 2% operationally.
Esperion Therapeutics lost a third of its value Wednesday after its cholesterol drug underperformed bullish expectations in a late-stage study.